AnalystsInsight

Whitney Ijem (Canaccord Genuity): Analyst Track Record and Price‑Target Accuracy

How often Whitney Ijem’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 711 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

#995 rank (was #927)+1 new rating (RARE)4.5★ rating (was 4.6★)

Key takeaways

  • Whitney Ijem ranks #878 of 1,000 analysts in Exent’s scoring (4.5★).
  • 23.8% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 113 days; 48.7% of calls were up 12 months later.
  • Most‑covered stocks: PVLA, GUTS, WVE, TSHA.
  • Free on Exent: Whitney Ijem’s full record, with ratings 3 days after publication.

Whitney Ijem’s track record at a glance

Whitney Ijem of Canaccord Genuity ranks #878 of the 1,000 analysts Exent scores, with a 4.5★ rating and a focus on healthcare. Over a 7‑year lookback, 23.8% of Whitney’s price targets were reached, 28.6 points below the 52.4% average across all analysts.

MetricWhitney IjemAll analysts
Price‑target hit rate23.8%52.4%
Median days to hit target113 days91 days
Calls up after 12 months48.7%64.0%
Median 12‑month return of calls−1.1%+13.4%
Hit rate, last 2 years25.2%—
Average worst drop after a call−30.8%—
Ratings in the sample711—
Stocks covered25—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetWhitney Ijem
Under 30 days12.0%
30–90 days25.3%
90–180 days37.3%
Over 180 days25.3%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Whitney Ijem covers most

StockRatings in the sample
PVLA43
GUTS37
WVE35
TSHA30
VRTX29
RYTM27
TNYA21
BMRN20

In the past year Whitney’s ratings were 94% Buy, 6% Hold and 0% Sell.

Whitney Ijem’s latest ratings

DateStockActionRatingPrice target
Sep 18, 2026RAREReiterated: BuyBuy$39.00
Sep 10, 2026OCGNReiterated: BuyBuy$11.00
Sep 9, 2026BEAMReiterated: BuyBuy$78.00
Sep 4, 2026BLTEInitiated Coverage: BuyBuy$303.00
Sep 3, 2026RAREReiterated: BuyBuy$37.00
Aug 31, 2026BMRNReiterated: BuyBuy$114.00
Aug 28, 2026ALNYReiterated: BuyBuy$429.00
Aug 20, 2026ARCTReiterated: BuyBuy$20.00
Aug 20, 2026RAREReiterated: BuyBuy$83.00
Aug 19, 2026BMRNReiterated: BuyBuy$114.00
Aug 12, 2026BBIOReiterated: BuyBuy$106.00
Aug 12, 2026GUTSReiterated: BuyBuy$8.00
  • Sep 18, 2026
    Stock
    RARE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $39.00
  • Sep 10, 2026
    Stock
    OCGN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $11.00
  • Sep 9, 2026
    Stock
    BEAM
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $78.00
  • Sep 4, 2026
    Stock
    BLTE
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $303.00
  • Sep 3, 2026
    Stock
    RARE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $37.00
  • Aug 31, 2026
    Stock
    BMRN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $114.00
  • Aug 28, 2026
    Stock
    ALNY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $429.00
  • Aug 20, 2026
    Stock
    ARCT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $20.00
  • Aug 20, 2026
    Stock
    RARE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $83.00
  • Aug 19, 2026
    Stock
    BMRN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $114.00
  • Aug 12, 2026
    Stock
    BBIO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $106.00
  • Aug 12, 2026
    Stock
    GUTS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $8.00

Whitney’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Whitney Ijem’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Whitney Ijem ranks #878 of 1,000 with a 4.5★ rating. 23.8% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 48.7% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Whitney Ijem’s success rate is 38.8% by the ranking source and 23.8% by Exent’s price-target hit-rate backtest, with a median of 113 days to reach a target.

Whitney Ijem (Canaccord Genuity) covers 25 stocks, mostly in healthcare. The most frequently rated are PVLA, GUTS, WVE, TSHA, VRTX.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.